HSV-2 gD (31-335)
Protein is >95% pure as determined by SDS-PAGE
Description
E.Coli derived HSV-2 gD recombinant protein, amino acids 31-335.
Product Specs
Product Science Overview
Herpes Simplex Virus-2 (HSV-2) is a significant human pathogen responsible for genital herpes. One of the critical components of HSV-2 is glycoprotein D (gD), which plays a crucial role in the virus’s ability to enter host cells. The recombinant form of this glycoprotein, specifically the segment spanning amino acids 31 to 335, has been extensively studied for its potential in vaccine development and therapeutic applications.
Glycoprotein D (gD) is an essential envelope protein of HSV-2. It is involved in the initial attachment and entry of the virus into host cells. The interaction between gD and host cell receptors is a critical step in the viral infection process. The segment from amino acids 31 to 335 of gD includes the receptor-binding domain, which is necessary for the virus to attach to and penetrate host cells .
The recombinant form of gD (31-335 a.a.) is produced using various expression systems, including bacterial, yeast, and mammalian cells. This recombinant protein retains the functional properties of the native glycoprotein, making it a valuable tool for research and therapeutic purposes. The recombinant gD (31-335 a.a.) has been used in vaccine development, aiming to elicit an immune response that can neutralize the virus and prevent infection .
Several studies have explored the use of recombinant gD (31-335 a.a.) in vaccine formulations. These vaccines aim to stimulate the immune system to produce antibodies against gD, thereby preventing the virus from entering host cells. Clinical trials have shown that vaccines containing recombinant gD can boost glycoprotein-specific and neutralizing antibodies, although the frequency of recurrent infections may not be significantly reduced .
Beyond vaccine development, recombinant gD (31-335 a.a.) has potential therapeutic applications. It can be used in diagnostic assays to detect HSV-2 infections and in research to study the virus’s entry mechanisms. Additionally, recombinant gD can be employed in immunotherapy strategies to enhance the immune response against HSV-2 .
